Preclinical Pharmacokinetic Pet Studies with Radiolabeled Potential New Drugs in Man

Positron Emission Tomography (PET) fosters the in vivo study of pharmacokinetics of drugs. The unrivalled sensitivity coupled with the very high specific activity with which possible new drugs can be labeled even allows pre-phase I biodistribution and structure-activity studies in man. The value of...

Full description

Saved in:
Bibliographic Details
Published in:Drug information journal 1997, Vol.31 (3), p.1015-1018
Main Author: Vaalburg, Willem
Format: Article
Language:English
Subjects:
Drugs
Emission analysis
In vivo methods and tests
Pharmaceuticals
Pharmacokinetics
Pharmacology
Positron emission
Positron emission tomography
Radiochemistry
Radioisotopes
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Positron Emission Tomography (PET) fosters the in vivo study of pharmacokinetics of drugs. The unrivalled sensitivity coupled with the very high specific activity with which possible new drugs can be labeled even allows pre-phase I biodistribution and structure-activity studies in man. The value of PET is illustrated by studies with S-1'-[18F]-fluorocarazolol, a recently developed radiopharmaceutical for in vivo studies of β-receptors in heart, lungs, and brain. Regulation aspects of such studies are discussed.
ISSN:2168-4790
0092-8615
2168-4804
2164-9200
DOI:10.1177/009286159703100345